Dr. Lebbe Discusses Efficacy of Avelumab in Merkel Cell Carcinoma

Celeste Lebbe, MD, PhD
Published: Monday, Oct 23, 2017



Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.

In a phase II study of avelumab, chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma, first-line treatment resulted in early responses and a high overall response rate (ORR) in this difficult-to-treat population.

The ORR was 62%, which occurred quite rapidly, says Lebbe. The median duration of response is not yet reached, though.
 


Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.

In a phase II study of avelumab, chemotherapy-naïve patients with distant metastatic Merkel cell carcinoma, first-line treatment resulted in early responses and a high overall response rate (ORR) in this difficult-to-treat population.

The ORR was 62%, which occurred quite rapidly, says Lebbe. The median duration of response is not yet reached, though.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Publication Bottom Border
Border Publication
x